Literature DB >> 17439416

5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes.

Yuji Odagaki1, Ryoichi Toyoshima.   

Abstract

1. 5-Hydroxytryptamine 1A (5-HT1A) receptors have attracted increasing attention as a promising target for antipsychotic therapy. Although many atypical antipsychotic drugs, including the prototype clozapine, have been reported to be partial agonists at 5-HT1A receptors, these results are often fragmental and derived mainly from experiments that used cultured cells. 2. In the present study, [35S]guanosine 5'-O-(3-thiotriphosphate) ([35S]GTPgammaS) binding assay in rat hippocampal membranes was applied to a series of antipsychotic drugs, especially atypical antipsychotics. 3. Most, but not all, of atypical antipsychotic drugs and the classical antipsychotic drug nemonapride behaved as partial agonists at 5-HT1A receptors with varied potencies and relative efficacies. The most potent compound was perospirone with a mean EC50 of 27 nmol/L, followed by aripiprazole (45 nmol/L) > ziprasidone (480 nmol/L) > nemonapride (790 nmol/L) > clozapine (3900 nmol/L) > quetiapine (26,000 nmol/L). The maximal percentage increases over the basal binding (%Emax) for these antipsychotic drugs were 30-50%, with the exception of perospirone (approximately 15%), whereas 5-HT stimulated the binding to a mean %Emax of 105%. 4. Increasing concentrations of the selective and neutral 5-HT1A antagonist WAY100635 shifted the concentration-response curve of nemonapride-stimulated [35S]GTPgammaS binding to the right and in parallel. 5. The relative efficacy or intrinsic activity of a compound was affected differently by the differing concentrations of guanosine diphosphate (GDP) in the assay buffer, which should be taken into consideration when determining the relative efficacies of these antipsychotics as 5-HT1A receptor agonists. 6. These results provide important information concerning the relevance of 5-HT1A receptor partial agonist properties in the treatment for schizophrenic patients with most, if not all, of atypical antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439416     DOI: 10.1111/j.1440-1681.2007.04595.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.

Authors:  Beryl Koener; Stéphanie Goursaud; Morgane Van De Stadt; André-Guilhem Calas; Anne P Jeanjean; Jean-Marie Maloteaux; Emmanuel Hermans
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01       Impact factor: 3.000

2.  Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of α1A/α1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth.

Authors:  Fernanda Chagas-Silva; Jéssica Barbosa Nascimento-Viana; Luiz Antonio S Romeiro; Luana C Barberato; François Noël; Claudia Lucia Martins Silva
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-10       Impact factor: 3.000

3.  Two cases of mild serotonin toxicity via 5-hydroxytryptamine 1A receptor stimulation.

Authors:  Hiroto Nakayama; Sumiyo Umeda; Masashi Nibuya; Takeshi Terao; Koichi Nisijima; Soichiro Nomura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-11       Impact factor: 2.570

Review 4.  HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis.

Authors:  Yoshiteru Takekita; Chiara Fabbri; Masaki Kato; Yosuke Koshikawa; Aran Tajika; Toshihiko Kinoshita; Alessandro Serretti
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-29       Impact factor: 5.176

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.